Metabolic Kinetics of Non-Hodgkin Lymphoma Prior to CAR-T Infusion: Prognostic Factors and Risk Stratification

Chimeric antigen receptor T-cell (CAR-T) therapy is utilized for patients with active non-Hodgkin lymphoma (NHL) refractory to recent treatments, sometimes even requiring bridging therapy during CAR-T manufacturing to maintain clinically stability for CAR-T infusion. We examined the metabolic kinetics of these patients' lymphoma via F-18 fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) with the hypothesis that...